Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder

Journal of Clinical Psychiatry

Volumn 67, Issue 11, 2006, Pages 1735-1740

  Moreno, Francisco A ^a,c   Wiegand, Christopher B ^a   Taitano, E Keolani ^a   Delgado, Pedro L ^b  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PSILOCYBINE;

ADULT; ANALYSIS OF VARIANCE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HYPERTENSION; MALE; OBSESSIVE COMPULSIVE DISORDER; OUTPATIENT DEPARTMENT; PRIORITY JOURNAL; PSYCHIATRIC DEPARTMENT; RATING SCALE; SINGLE DRUG DOSE; VISUAL ANALOG SCALE; VITAL SIGN;

EID: 33845649411     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v67n1110     Document Type: Article

References (30)

1. Karno M, Golding JM, Sorenson SB, et al. The epidemiology of obsessive compulsive disorder in 5 US communities. Arch Gen Psychiatry 1988;45:1094-1099
2. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Arch Gen Psychiatry 1994;51:8-19
3. Murray CJL, Lopez AD, eds. A Comprehensive Assessment of Mortality and Disability From Diseases, Injuries, and Risk Factors in 1990 and Projected to 2020: The Global Burden of Disease. Cambridge, Mass: The Harvard School of Public Health, on Behalf of the World Health Organization and The World Bank; 1996
4. Greist JH, Jefferson JW, Kobak KA. Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder: a meta-analysis. Arch Gen Psychiatry 1995;52:53-60
5. Expert Consensus Guideline Series: Treatment of Obsessive Compulsive Disorder. J Clin Psychiatry 1997;58(suppl 4):1-72
6. Benkelfat C, Murphy DL, Zohar J. Clomipramine in obsessive-compulsive disorder: further evidence for a serotonergic mechanism of action. Arch Gen Psychiatry 1989;46:23-28
7. Goodman WK, Price LH, Delgado PL, et al. Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder. Arch Gen Psychiatry 1990;47:577-585
8. Vulink NCC, Denys D, Westenberg HGM. Bupropion for patients with obsessive-compulsive disorder: an open-label, fixed-dose study. J Clin Psychiatry 2005;66:228-230
9. Goodman WK. Obsessive-compulsive disorder: diagnosis and treatment. J Clin Psychiatry 1999;60(suppl 18):27-32
10. Brandrup E, Vanggaard T. LSD treatment in a severe case of compulsive neurosis. Acta Psychiatr Scand 1977;55:127-141
11. Leonard HL, Rapoport JL. Relief of obsessive-compulsive symptoms by LSD and psilocybin [letter]. Am J Psychiatry 1987;144:1239-1240
12. Hanes KR. Serotonin, psilocybin, and body dysmorphic disorder: a case report [letter]. J Clin Psychopharmacol 1996;16:188-189
13. Delgado PL, Moreno FA. Hallucinogens, serotonin, and obsessive-compulsive disorder. J Psychoactive Drugs 1998;30:359-366
14. Anonymous. Personal account of mushrooms curing obsessive-compulsive disorder. Bull Multidisciplinary Assoc Psychedelic Stud 2002;12:17
15. Moreno FA, Delgado PL. Hallucinogen-induced relief of obsessions and compulsions [letter]. Am J Psychiatry 1997;154:1037-1038
16. Glennon RA, Titeler M, McKenney JD. Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents. Life Sci 1984;35:2505-2511
17. McKenna DJ, Repke DB, Lo L, et al. Differential interactions of indolealkylamines with 5-hydroxytryptamine receptor subtypes. Neuropharmacology 1990;29:193-198
18. Aghajanian GK, Marek GJ. Serotonin and hallucinogens. Neuropsychopharmacology 1999;21(suppl 2):16S-23S
19. Vollenweider FX, Vollenweider-Scherpenhuyzen MF, Babler A, et al. Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. Neuroreport 1998;9:3897-3902
20. Passie T, Seifert J, Schneider U, et al. The pharmacology of psilocybin. Addict Biol 2002;7:357-364
21. Hasler F, Grimberg U, Benz MA. Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose-effect study. Psychopharmacology 2004;172:145-156
22. First MB, Gibbon M, Spitzer RL, et al. User's Guide for the Structured Interview for DSM-IV Axis I Disorders-Research Version (SCID-I, version 2.0). New York, NY: Biometric Research, New York State Psychiatric Institute; 1996
23. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994
24. Goodman WK, Price LH, Rasmussen SA, et al. The Yale-Brown Obsessive Compulsive Scale, 1: development, use, and reliability. Arch Gen Psychiatry 1989;46:1006-1011
25. Riba J, Rodriguez-Fornells A, Strassman RJ, et al. Psychometric assessment of the Hallucinogen Rating Scale. Drug Alcohol Depend 2001;62:215-223
26. Norusis MJ. SPSS 13 Base System User's Guide. Chicago, Ill: SPSS Inc; 2005
27. SYSTAT 11. Point Richmond, Calif: Systat Software, Inc; 2005
28. Gresch PJ, Smith RL, Barrett RJ, et al. Behavioral tolerance to lysergic acid diethylamide is associated with reduced serotonin-2A receptor signaling in rat cortex. Neuropsychopharmacology 2005;30:1693-1702
29. Backstrom JR, Chang MS, Chu H, et al. Agonist-directed signaling of serotonin 5-HT2C receptors: differences between serotonin and lysergic acid diethylamide (LSD). Neuropsychopharmacology 1999; 21:77S-81S
30. Nichols CD, Sanders-Bush E. A single dose of lysergic acid diethylamide influences gene expression patterns within the mammalian brain. Neuropsychopharmacology 2002;26:634-642